التجارب السريرية بالأسفل التجارب السريرية الحالية.22 دراسات في طب الأمراض الجلدية (افتح الدراسات فقط). غربل قائمة الدراسات هذه بالموقع والحالة وغيرها. A Study to Collect Long-Term Data on Pediatric Cutaneous Mastocytosis Rochester, Minn. The purpose of this study is to develop a registry to collect long-term data on patients with pediatric cutaneous mastocytosis, and develop better knowledge of the timing, symptoms, resolution or progression of the disease, and predictive markers of its severity. A Study to Evaluate Immunotherapy and Ovarian Function Among Pre-menopausal Melanoma Survivors Rochester, Minn. The purposes of this study are to analyze the ovarian function of female premenopausal melanoma survivors who have undergone immunotherapy, and compare with data from age-matched controls, prospectively investigate ovarian function in premenopausal women with melanoma undergoing immunotherapy, and to identify the impact of ovarian function change on the frequency and function of CD8+ T cells during immunotherapy. SX-682 Treatment in Subjects With Metastatic Melanoma Concurrently Treated With Pembrolizumab Rochester, Minn. The primary objective of this study is to determine the safety profile of SX-682 alone and in combination with pembrolizumab in subjects with metastatic melanoma, including the maximum dose that can be administered until adverse effects prevent further dose increases (i.e., the MTD or recommended phase 2 dose), and the dose-limiting toxicity (DLT). The secondary objectives are to evaluate the efficacy of SX-682 in combination with pembrolizumab on the basis of the objective response rate, the duration of response, and the rate of progression, and to characterize the single-dose and multidose pharmacokinetic (PK) profile of SX-682. A Study to Evaluate Ipilimumab Administered Intra-lymphatically Using the Sofusa® DoseConnect™ DEVICE with IV-administered Nivolumab in Patients with Metastatic Melanoma Rochester, Minn. The primary objective of the overall study is to determine the maximum tolerated dose (MTD) of ipilimumab that can be administered through the DoseConnect™ device, followed 30 minutes later by nivolumab IV on Day 1 of a 21-day cycle in patients with metastatic melanoma. PRA023 in Subjects with Systemic Sclerosis Associated with Interstitial Lung Disease Scottsdale/Phoenix, Ariz. The purpose of this study is to assess the safety, tolerability, and effectiveness of PRA023 in subjects with Systemic Sclerosis (SSc) with diffuse cutaneous disease and Interstitial Lung Disease (ILD). A Study to Evaluate Platelet Rich Plasma to Treat Vulvar Lichen Sclerosus Jacksonville, Fla. The purposes of this study are to determine the safety and feasibility of autologous platelet-rich plasma for the treatment of vulvar lichen sclerosus, and to determine the efficacy of autologous platelet-rich plasma for the treatment of vulvar lichen sclerosus. MElanoma Research Lymph node prediction Implementation National_001 (MERLIN_001) Rochester, Minn. This study aims to create a registry for primary melanoma gene-signature to predict sentinel node (SN) status and determine its prognostic value for more accurate staging of SN-negative melanoma patients. Study to Analyze the Metabolic Environment in Preventing Atopic Dermatitis Rochester, Minn. The purpose of this study is to compare the assessment of the composition of the fecal, nasal,oral and skin microbiota in patients with AD (cases) as compared to age/sex and diet matched control children without atopic dermatitis, and to apply mass-spectrometry-based metabolomic approach to analyzing fecal, nasal, oral and skin samples from cases, in order to characterize their biochemical metabolic profiles by comparison with those of their controls. A Study to Evaluate the Effectiveness and Tolerability of a Topical Composition Therapy for the Treatment of Cutaneous Mastocytosis Rochester, Minn. The purpose of this study is to determine the effectiveness and tolerability of a novel topical preparation for the treatment of cutaneous lesions of mastocytosis. A Study of Sonidegib and Pembrolizumab in Advanced Solid Tumors Rochester, Minn., Jacksonville, Fla., Scottsdale/Phoenix, Ariz. The purpose of this study is to determine the maximum tolerated dose (MTD) of sonidegib in combination with pembrolizumab in participants with advanced solid tumors as part of the dose escalation phase, and to estimate the response rate of sonidegib in combination with pembrolizumab in participants with NSCLC or pancreas cancer as part of the expansion cohort based on RECIST criteria. التصفّح دراسات سريرية توجّه للصفحة 11 توجّه للصفحة 22 توجّه للصفحة 33 التاليالصفحة التالية طلب تحديد موعد المواقع والسفر والإقامةالبحث 22/09/2023 تبادلها عبر ارسلها على الفيس بوكارسلها في تغريدة بالأسفل التجارب السريرية الحالية.22 دراسات في طب الأمراض الجلدية (افتح الدراسات فقط). غربل قائمة الدراسات هذه بالموقع والحالة وغيرها. A Study to Collect Long-Term Data on Pediatric Cutaneous Mastocytosis Rochester, Minn. The purpose of this study is to develop a registry to collect long-term data on patients with pediatric cutaneous mastocytosis, and develop better knowledge of the timing, symptoms, resolution or progression of the disease, and predictive markers of its severity. A Study to Evaluate Immunotherapy and Ovarian Function Among Pre-menopausal Melanoma Survivors Rochester, Minn. The purposes of this study are to analyze the ovarian function of female premenopausal melanoma survivors who have undergone immunotherapy, and compare with data from age-matched controls, prospectively investigate ovarian function in premenopausal women with melanoma undergoing immunotherapy, and to identify the impact of ovarian function change on the frequency and function of CD8+ T cells during immunotherapy. SX-682 Treatment in Subjects With Metastatic Melanoma Concurrently Treated With Pembrolizumab Rochester, Minn. The primary objective of this study is to determine the safety profile of SX-682 alone and in combination with pembrolizumab in subjects with metastatic melanoma, including the maximum dose that can be administered until adverse effects prevent further dose increases (i.e., the MTD or recommended phase 2 dose), and the dose-limiting toxicity (DLT). The secondary objectives are to evaluate the efficacy of SX-682 in combination with pembrolizumab on the basis of the objective response rate, the duration of response, and the rate of progression, and to characterize the single-dose and multidose pharmacokinetic (PK) profile of SX-682. A Study to Evaluate Ipilimumab Administered Intra-lymphatically Using the Sofusa® DoseConnect™ DEVICE with IV-administered Nivolumab in Patients with Metastatic Melanoma Rochester, Minn. The primary objective of the overall study is to determine the maximum tolerated dose (MTD) of ipilimumab that can be administered through the DoseConnect™ device, followed 30 minutes later by nivolumab IV on Day 1 of a 21-day cycle in patients with metastatic melanoma. A Study to Evaluate Platelet Rich Plasma to Treat Vulvar Lichen Sclerosus Jacksonville, Fla. The purposes of this study are to determine the safety and feasibility of autologous platelet-rich plasma for the treatment of vulvar lichen sclerosus, and to determine the efficacy of autologous platelet-rich plasma for the treatment of vulvar lichen sclerosus. PRA023 in Subjects with Systemic Sclerosis Associated with Interstitial Lung Disease Scottsdale/Phoenix, Ariz. The purpose of this study is to assess the safety, tolerability, and effectiveness of PRA023 in subjects with Systemic Sclerosis (SSc) with diffuse cutaneous disease and Interstitial Lung Disease (ILD). MElanoma Research Lymph node prediction Implementation National_001 (MERLIN_001) Rochester, Minn. This study aims to create a registry for primary melanoma gene-signature to predict sentinel node (SN) status and determine its prognostic value for more accurate staging of SN-negative melanoma patients. A Study to Evaluate the Effectiveness and Tolerability of a Topical Composition Therapy for the Treatment of Cutaneous Mastocytosis Rochester, Minn. The purpose of this study is to determine the effectiveness and tolerability of a novel topical preparation for the treatment of cutaneous lesions of mastocytosis. Study to Analyze the Metabolic Environment in Preventing Atopic Dermatitis Rochester, Minn. The purpose of this study is to compare the assessment of the composition of the fecal, nasal,oral and skin microbiota in patients with AD (cases) as compared to age/sex and diet matched control children without atopic dermatitis, and to apply mass-spectrometry-based metabolomic approach to analyzing fecal, nasal, oral and skin samples from cases, in order to characterize their biochemical metabolic profiles by comparison with those of their controls. A Study to Evaluate the Effectiveness and Safety of PCS499 in Treating Ulcerations in Patients who have Necrobiosis Lipoidica Scottsdale/Phoenix, Ariz., Rochester, Minn. The purpose of this study is to evaluate the effectiveness of PCS499 at 6 Months in treating ulcerations in patients who have necrobiosis lipoidica. التصفّح دراسات سريرية توجّه للصفحة 11 توجّه للصفحة 22 توجّه للصفحة 33 التاليالصفحة التالية طب الأمراض الجلديةالأقسامطلب تحديد موعدمُلخّصالاختبارات والإجراءاتحالات تم علاجهاالأطباءالمجموعات المتخصصةالمواقع والسفر والإقامةالتجارب السريريةالبحثتجارب Mayo Clinic وقصص المرضىالتكاليف والتأمينأخبار Mayo Clinicإحالةالمرضى الأبحاث: الأمر برمته يتوقف على المرضى إظهار النسخة النصية للفيديو الأبحاث: الأمر برمته يتوقف على المرضى [MUSIC PLAYING] Joseph Sirven, M.D., Professor of Neurology, Mayo Clinic: Mayo's mission is about the patient. The patient comes first. So the mission and research here is to advance how we can best help the patient, how to make sure the patient comes first in care. So in many ways, it's a cycle. It can start with as simple as an idea worked on in a laboratory, brought to the patient bedside, and if everything goes right — and let's say it's helpful or beneficial — then brought on as a standard approach. And I think that is one of the unique characteristics of Mayo's approach to research — that patient-centeredness — that really helps to put it in its own spotlight. الأقسامطلب تحديد موعدمُلخّصالاختبارات والإجراءاتحالات تم علاجهاالأطباءالمجموعات المتخصصةالمواقع والسفر والإقامةالتجارب السريريةالبحثتجارب Mayo Clinic وقصص المرضىالتكاليف والتأمينأخبار Mayo Clinicإحالة المرضى ORG-20420337 الأقسام والمراكز الطبية طب الأمراض الجلدية